Details

Autor(en) / Beteiligte

• Hinze, Claas
• Fuehner, Sabrina
• Kessel, Christoph
• Wittkowski, Helmut
• Lainka, Elke
• Baehr, Melanie
• Hügle, Boris
• Haas, Johannes‐Peter
• Ganser, Gerd
• Weißbarth‐Riedel, Elisabeth
• Jansson, Annette
• Foell, Dirk

Titel

Impact of IL1RN Variants on Response to Interleukin‐1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis

Ist Teil von

• Arthritis & rheumatology (Hoboken, N.J.), 2020-03, Vol.72 (3), p.499-505

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Wiley-Blackwell Full Collection

Beschreibungen/Notizen

• Objective To analyze the reported association of IL1RN polymorphisms with response to interleukin‐1 (IL‐1) blockade in a German cohort of patients with systemic juvenile idiopathic arthritis (JIA), and to assess the impact of other factors on treatment response. Methods Sixty‐one patients with systemic JIA who had received IL‐1 blockade were identified within the German Autoinflammatory Disease registry DNA biobank. Response to IL‐1 blockade was assessed according to 1) the clinical response (initially at least a transient response or good response compared to a poor response), 2) switch (or no switch) to anti–IL‐6 receptor therapy following IL‐1 blockade, 3) achievement of clinically inactive disease within 6 months of IL‐1 blockade, 4) improvement in disease activity measured using the modified Juvenile Arthritis Disease Activity Score, and 5) achievement of a glucocorticoid‐free state. In addition, basic demographic data, key features of the disease course, laboratory data, and IL1RN single‐nucleotide polymorphisms (SNPs) were assessed. Results Six of 7 IL1RN SNPs reported to be associated with response to anakinra therapy were analyzed. These 6 IL1RN SNPs were inherited as haplotypes. An association of IL1RN haplotypes and SNPs with response to IL‐1 blockade could not be confirmed in this cohort of patients with systemic JIA. Patients who received tocilizumab following IL‐1 blockade had a longer duration from disease onset to diagnosis than those who did not receive tocilizumab (median 0.27 years versus 0.08 years). Conclusion The results of this study could not confirm an impact of IL1RN SNPs on response to IL‐1 blockade therapy with either anakinra or canakinumab in a cohort of patients with systemic JIA. However, a longer time frame from disease onset to diagnosis was associated with poorer long‐term treatment response, thereby supporting the “window of opportunity” hypothesis that suggests improved long‐term treatment response with shorter time from disease onset to diagnosis (and treatment).